The Blockcluster Model: An Alternate Path To Profitability
Executive Summary
As blockbuster pipelines dwindle, some large manufacturers see building portfolios of drugs for narrow, related clusters of indications as significant market opportunities. Companies such as GSK, Genzyme, Novartis and Pfizer are finding success with assets that truly address an unmet need and have the potential to be reimbursed at a premium price. However, in many cases, the development and commercialization of narrow-indication drugs are not easy tasks.
You may also be interested in...
Xalkori And The Art Of Modern Drug Development
Pfizer developed crizotinib and its companion diagnostic in just four years after identifying an aberrant ALK gene as the target, spanning a corporate restructuring, the Wyeth integration, and the departure of senior staff in the R&D organization and oncology BU. The next year or so will tell whether Xalkori was a flash in the pan, or whether it marks the long awaited turnaround for Pfizer’s oncology business and a model for nimble drug development.
Orphaned No Longer: Big Pharma Embraces Drugs for Niche Markets
Hit hard by late stage pipeline failures and the regulatory and reimbursement challenges of traditional primary care products, Big Pharmas are taking renewed interest in drugs for orphan diseases, where high unmet medical need offers the promise of premium pricing and there's potential to grow the market via approval in multiple indications.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”